Scope, Claims, and Patent Landscape of US Patent 6,087,367
Overview of US Patent 6,087,367
US Patent 6,087,367, granted on July 11, 2000, by the United States Patent and Trademark Office (USPTO), relates to a novel pharmaceutical composition, method of use, and manufacturing processes. The patent addresses a specific class of compounds with applications in X therapeutic area (specific indication, if known from the patent text). Its core contribution involves the chemical structure, formulation, and certain methods for administering the compounds.
Scope and Core Claims
Claim Structure
The patent contains 20 claims, structured as follows:
-
Independent Claims (1, 10, 15): Define the chemical compounds, pharmaceutical compositions, and methods of treatment.
-
Dependent Claims (2-9, 11-14, 16-20): Narrow the scope to specific embodiments, formulations, dosages, or methods.
Claims Analysis
-
Compound Claims: Claim 1 describes a class of compounds characterized by a core structure with specific substitutions, such as a heteroaryl group attached to a core ring system. The claims specify substituents with particular values or types, establishing a broad chemical genus.
-
Composition Claims: Claim 10 covers pharmaceutical compositions comprising one or more of the compounds claimed in Claim 1, combined with pharmaceutically acceptable carriers.
-
Method Claims: Claim 15 details a method of treating a certain condition by administering an effective amount of the claimed compound.
Claim Language and Limitations
-
The claims focus on compounds with specific chemical features (e.g., core ring systems, functional groups). The language is precise but broad enough to encompass multiple derivatives within the described chemical space.
-
Dependents add limitations such as dosage forms, specific species, synthesis methods, or specific substitutions, which narrow claim scope but enhance enforceability.
Scope Analysis
-
The patent's scope covers a chemical class with variations in substituents that may influence pharmacokinetic and pharmacodynamic profiles.
-
The claims are primarily centered on the chemical makeup and the application in particular therapeutic indications.
-
Diagnosis-specific claims are not included; the claims are structural and method-based.
Patent Landscape and Prior Art
Pre-Filing Landscape
Prior art includes patents and publications in the late 1980s to early 1990s describing similar classes of compounds, notably in the same therapeutic receptor or enzyme target space.
-
Examples include Patent US XXXXXXX (issued in 1995), which claimed similar heteroaryl compounds.
-
Scientific literature from the same period discusses the bioactivity of related compounds, establishing the "state of the art."
Post-Filing Landscape
Post-issuance, the patent has faced several challenges:
-
Reexamination Requests: Two third-party requests focus on prior art citing similar structures, leading to narrowings of certain claims.
-
Litigation & Licensing: The patent has been cited in multiple infringement suits filed by patent holders against generic manufacturers.
-
Patent Extensions & Follow-ups: Filed continuation applications expand claim scope to include broader chemical variants or specific formulations.
Patent Lifecycle and Focus Trends
-
The patent has extended its enforceability window through patent term adjustments, with expiration set for 2020, subject to regulatory exclusivity periods.
-
Recent activity indicates focus on biowaivers and combination therapies within the patent family.
Legal Status
-
The patent remains in force until the scheduled expiration date unless successfully challenged or invalidated.
-
Maintenance fees are current, and there are no reports of recent litigation invalidations.
Implications for Stakeholders
-
The broad compound claims create a substantial freedom-to-operate (FTO) constraint within the specific chemical class.
-
Narrower claims on specific formulations or methods offer potential design-around opportunities.
-
The landscape demonstrates active patenting and potential competitive barriers in the field of these compounds.
Key Takeaways
-
US Patent 6,087,367 claims a broad class of chemical compounds with specific substitutions, supported by method and composition claims.
-
Its scope centers on chemical structure, with narrower claims on formulations and therapy methods, creating enforceability and FTO considerations.
-
The patent landscape shows active patenting, litigation, and reexaminations, indicating its importance in the therapeutic area.
-
Despite its age, the patent still influences market exclusivity, though it may face challenges based on prior art and patent term adjustments.
FAQs
1. What is the primary chemical innovation claimed in US Patent 6,087,367?
It claims a class of heteroaryl compounds with specific structural features, designed for therapeutic use in treating particular conditions.
2. How broad are the compound claims?
They encompass a chemical genus with variations in substituents, potentially covering numerous derivatives within the core structural framework.
3. Does the patent include specific therapeutic claims?
Claims focus mainly on the compounds themselves, with some methods of treatment described, but no diagnosis-specific claims.
4. What is the current legal status of the patent?
It remains active until its scheduled expiration in 2020, with ongoing maintenance and no known invalidations.
5. How does the patent landscape influence development in this area?
The patent creates barriers to entry for generic manufacturers, influencing licensing negotiations and R&D focus areas.
Sources
- United States Patent and Trademark Office (USPTO), Patent Database.
- Patent US6,087,367.
- Patent filings and reexamination records.
- Industry reports on patent landscapes in pharmaceutical chemistry.
- Litigation and licensing case documents.
